FTC and DOJ to Host Listening Sessions on Lowering Americans’ Drug Prices Through Competition

As part of implementing President Trump’s Executive Order No. 14273, Lowering Drug Prices by Once Again Putting Americans First, the Federal Trade Commission and the Justice Department’s Antitrust Division, along with the Department of Commerce and the Department of Health and Human Services, will jointly host listening sessions to discuss ways to make prescription drugs more affordable for Americans by promoting competition. The three listening sessions will occur under the direction of FTC Chairman Andrew N. Ferguson and Assistant Attorney General Gail Slater of the DOJ Antitrust Division.

The listening sessions will focus on improving the affordability of pharmaceuticals by increasing generic and biosimilar availability and promoting competition through drug formularies and benefits. The sessions, which will feature remarks by practitioners and scholars, will cover anticompetitive practices as well as eliminating regulatory barriers and rent seeking. The listening sessions will inform the FTC and DOJ’s joint report on combatting anticompetitive practices in pharmaceutical markets, as mandated by President Trump’s Executive Order.

The dates for the sessions are as follows:

• Monday, June 30 at 2 pm ET – Anticompetitive Conduct by Pharmaceutical Companies Impeding Generic or Biosimilar Competition
• Thursday, July 24 at 2 pm ET – Formulary and Benefit Practices and Regulatory Abuse Impacting Drug Competition
• Monday, August 4 at 2 pm ET – Turning Insights into Action to Reduce Drug Prices

The listening sessions will be streamed on the FTC and DOJ websites, with videos and transcripts posted after the events. Additional information will be posted to the event page prior to each session.